Bio Briefs
Posted By
Recent Posts on This Topic | See All >
[Source: The Arizona Republic] - A Mesa-based company that markets a drug-analysis technology has completed its first examination of an investigational cancer drug being developed by a Canadian biotechnology company.
Predictive Biomarker Sciences, a for-profit company partly owned by Phoenix-based Translational Genomics Research Institute, analyzed a drug candidate being developed by Ottawa, Ontario-based PharmaGap. The analysis suggested that PharmaGap's potential drug, called GAP-107B8, attacks the membrane of colon cancer cells while having less impact on non-cancerous cells.
For more information: Mesa-based Predictive Biomarker Sciences tests cancer drug
Quick Links
![]()
“A Bridge Crossed,” a brochure featuring the 2012 progress of Arizona’s Bioscience Roadmap, as well as "Performance Assessment 2002-12," featuring the latest bioscience sector data from Battelle Technology Partnership Practice, are now available.


Share on Twitter
Share on Facebook


